Search clinical trials for: MEK 162

Total 5611 results

M.D. Anderson Cancer Center
Array BioPharma

Terminated

MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy

Leukemia

United States
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Recurrent Melanoma | Stage IV Melanoma

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia

Insomnia

United States
UniQure Biopharma B.V.

Not yet recruiting

Safety, Tolerability, and Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Amyotrophic Lateral Sclerosis (ALS) Patients With SOD1 Mutations

Amyotrophic Lateral Sclerosis
Vanda Pharmaceuticals

Completed

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Circadian Rhythm Sleep Disorders

United States
Beijing Shenogen Biomedical Co., Ltd
307 Hospital of PLA; Cancer Institute and Hospital, Chinese Academy of Medical... and other collaborators

Completed

The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma (HCC)

China
Vanda Pharmaceuticals

Completed

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
Allergan

Completed

A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

Migraine
Yale University
National Cancer Institute (NCI)

Completed

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS) | Chronic Myeloid Leukemia (CML)

United States
Vanda Pharmaceuticals

Completed

VEC-162 Study in Adult Patients With Primary Insomnia

Primary Insomnia

United States
Vanda Pharmaceuticals

Active, not recruiting

Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception

Non 24 Hour Sleep Wake Disorder

France
Cancer Institute and Hospital, Chinese Academy...
Beijing Shenogen Biomedical Co., Ltd

Completed

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

Solid Tumors

China
Vanda Pharmaceuticals

Completed

Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception

Non-24-Hour Sleep-Wake Disorder

United States
Vanda Pharmaceuticals

Completed

Pharmacokinetics of Tasimelteon in Subjects With Renal Impairment and Matched Control Subjects With Relatively Normal Renal Function

Renal Impairment

United States
Biocad

Completed

The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis (AURORA)

Seropositive RA

Russian Federation, Belarus
Vanda Pharmaceuticals

Completed

Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder

United States, Germany
Amgen

Completed

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Bone Metastases in Men With Hormone-Refractory Prostate Cancer | Bone Metastases in Subjects With Advanced Breast Cancer | Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Amgen

Completed

A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects

Osteoporosis
Merck Sharp & Dohme LLC

Completed

Adjuvant Treatment With a Glycine Uptake Inhibitor in Participants With Negative Symptoms of Schizophrenia (P05695) (MK-8435-001) (GIANT)

Schizophrenia
University Health Network, Toronto

Withdrawn

A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer

Gallbladder Carcinoma | Biliary Tract Carcinoma
Vanda Pharmaceuticals

Completed

Effects of Smoking, Age and Body Size on Pharmacokinetics, Safety and Tolerability on Tasimelteon in Healthy Subjects

Healthy Volunteers

United States
SpringWorks Therapeutics, Inc.

Available

Individual Patient Compassionate Use of Mirdametinib

Neurofibromatosis Type 1-Associated Plexiform Neurofibromas | Histiocytic Neoplasm | Other MAP-K Pathway Driven Diseases
EMS

Withdrawn

Efficacy of Fixed-doses of Antihypertensive and Statin Drugs

Hypertension | Dyslipidemia
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Solid Tumor

China
Neothetics, Inc

Completed

A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

Weight

United States
CStone Pharmaceuticals

Completed

A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors

Solid Tumor, Adult

Australia
Chonbuk National University Hospital

Completed

Efficacy of an Extract of Concentrated Korean Red Ginseng for Preventing Upper Respiratory Tract Infections

Healthy Subjects

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)

Solid Neoplasms

United States, Canada, Israel, Korea, Republic of
Yangshengtang Co., Ltd

Not yet recruiting

A Clinical Study of 162 in Subjects With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B Virus Infection
Yangshengtang Co., Ltd
Syneos Health

Completed

Phase 1 Study of 162, a Novel Neutralizing Antibody Targeting Hepatitis B Surface Antigen, in Healthy Adult Subjects

Chronic Hepatitis B

Australia
Italian Society of Nephrology
European Commission; Memorial University of Newfoundland

Terminated

Bicarbonate v Saline to Prevent Contrast Nephropathy

Kidney Failure, Acute | Contrast Media

Italy
Bayer

Completed

To Evaluate Eye Installation-Tear Free

Sunscreening Agents

United States
Taisho Pharmaceutical R&D Inc.

Completed

First-in-Human Study With Single and Multiple Doses of TS-161 in Healthy Participants

Healthy Volunteers

United States
Jonsson Comprehensive Cancer Center
Merck Sharp & Dohme LLC; Highlight Therapeutics

Terminated

BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Advanced Hepatocellular Carcinoma | BCLC Stage B Hepatocellular Carcinoma | BCLC Stage C Hepatocellular Carcinoma | Refractory Hepatocellular Carcinoma

United States
Cancer Institute and Hospital, Chinese Academy...
Beijing Shenogen Biomedical Co., Ltd

Unknown

Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients

Metastatic Breast Cancer

China
Roswell Park Cancer Institute
Amgen

Completed

Denosumab in Treating Patients With Bone Loss Due to Donor Stem Cell Transplant

Osteoporosis | Osteopenia | Allogeneic Hematopoietic Stem Cell Transplantation Recipient

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Abbott

Completed

Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia

Schizophrenia

United States
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
ALK-Abelló A/S
Merck Sharp & Dohme LLC

Completed

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Nonseasonal
Array Biopharma, now a wholly owned subsidiary...

Completed

A Study of ARRY-142886 in Patients With Advanced Cancer

Advanced Cancer

United States
CinDome Pharma, Inc.

Completed

A Phase 2 Study of CIN-102 in Adults With Idiopathic and Diabetic Gastroparesis

Gastroparesis

United States
Terumo Europe N.V.

Recruiting

Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma. (HOMIE-166)

Hepatocellular Carcinoma

Germany
Beijing Shenogen Biomedical Co., Ltd
The First Affiliated Hospital with Nanjing Medical University; Guilin Medical... and other collaborators

Unknown

The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects

Advanced HBV-Related Hepatocellular Carcinoma (HCC)

China
Northwestern University
National Cancer Institute (NCI); Amgen

Terminated

Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells

Stage IV Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Breast Carcinoma Metastatic in the Bone | Circulating Tumor Cell Count

United States
Heidelberg University
Merck Sharp & Dohme LLC

Recruiting

Effects of Riociguat on RIght VEntricular Size and Function in PAH and CTEPH (RIVERII)

Chronic Thromboembolic Pulmonary Hypertension | Primary Pulmonary Arterial Hypertension

Germany
Taisho Pharmaceutical Co., Ltd.

Completed

Long-Term Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan

Search clinical trials for: MEK 162

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations